Influence of ABCB1 genetic variants in breast cancer treatment outcomes

Cancer Epidemiology

Volumn 37, Issue 5, 2013, Pages 754-761

  Chaturvedi, P ^a   Tulsyan, S ^a   Agarwal, G ^a   Lal, P ^a   Agarwal, S ^a   Mittal, R D ^a   Mittal, B ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Breast cancer; Multi drug resistance gene; Polymorphism; Response; Toxicity; Treatment outcomes

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ALLELE; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; DNA POLYMORPHISM; FEBRILE NEUTROPENIA; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

BREAST CANCER; MULTI DRUG RESISTANCE GENE; POLYMORPHISM; RESPONSE; TOXICITY; TREATMENT OUTCOMES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 84884146302     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.04.012     Document Type: Article

References (26)

1. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
2. Rodrigues F.F., Santos R.E., Melo M.B., Silva M.A., Oliveira A.L., Rozenowicz R.L., et al. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res 2008, 7(1):177-183.
3. Evans W.E., McLeod H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
4. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer 2002, 2:48-58.
5. Burger H., Foekens J.A., Look M.P., Gelder M.E., Klijn J.G., Wiemer E.A., et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003, 9:827-836.
6. Mutoh K., Tsukahara S., Mitsuhashi J., Katayama K., Sugimoto Y. Estrogen mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 2006, 97:1198-1204.
7. Chen C.J., Clark D., Ueda K., Pastan I., Gottesman M.M., Roninson IB Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990, 265:506-514.
8. Fojo A., Lebo R., Shimizu N., Chin J.E., Roninson I.B., Merlino G.T., et al. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet 1986, 12:415-420.
9. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001, 70:189-199.
10. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR gene in white subjects. Clin Pharmacol Ther 2001, 69:169-174.
11. Kafka A., Sauer G., Jaeger C., Grundmann R., Kreinberg R., Zeillinger R., et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003, 22:1117-1121.
12. Cizmarikova M., Wagnerova M., Schonova L., Habalova V., Kohut A., Linkova M., et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010, 10:62-69.
13. Zhang B.L., Sun T., Zhang B.N., Zheng S., Lu N., Xu B.H., et al. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl) 2011, 124:199-204.
14. Tsai S.M., Lin C.Y., Wu S.H., Hou L.A., Ma H., Tsai L.Y., et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 2009, 404(2):160-165.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
16. Cancer Therapy Evaluation Program Common terminology criteria for adverse events, version 3.0 2003, DCTD, NCI, NIH, DHHS, [accessed 13.02.13]. http://ctep.cancer.gov/.
17. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215.
18. Hamdy S.I., Hiratsuka M., Narahara K., Endo N., Enany M., Moursi N., et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 2003, 55:560-569.
19. Gauderman W.J. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 2002, 21(1):35-50.
20. Cochran W. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
21. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
22. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
23. Chang H., Rha S.Y., Jeung H.C., Im C.K., Ahn J.B., Kwon W.S., et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009, 20:272-277.
24. George J., Dharanipragada K., Krishnamachari S., Chandrasekaran A., Sam S.S., Sunder E. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 2009, 9:161-165.
25. Leonessa F., Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003, 10:43-73.
26. Ji M., Tang J., Zhao J., Xu B., Qin J., Lu J. Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther 2012, 13(5):264-271.